2-pyrrolino-dox profile

AN 204: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	119196
MeSH ID	M0259355

Synonym
3'-deamino-3'-(2''-pyrroline-1''-yl)doxorubicin trifluoroacetate
an 204
2-pyrrolino-dox
2-pyrrolinodoxorubicin
an 201
5,12-naphthacenedione, 7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-10-((2,3,6-trideoxy-3-(2,3-dihydro-1h-pyrrol-1-yl)-alpha-l-lyxo-hexopyranosyl)oxy)-, (8s-cis)-
an-204
175795-76-3
an-201
(7s,9s)-7-[(2r,4s,5s,6s)-4-(2,3-dihydropyrrol-1-yl)-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione
DTXSID50938708
3,5,12-trihydroxy-3-(hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 2,3,6-trideoxy-3-(2,3-dihydro-1h-pyrrol-1-yl)hexopyranoside

Excerpt	Relevance	Reference
"Tumor inhibitory action and the optimal dosage regimens of highly potent targeted cytotoxic luteinizing hormone releasing hormone (LH-RH) analogs containing doxorubicin (DOX) or 2-pyrrolino-DOX (AN-201) were tested in female BDF mice bearing estrogen independent MXT mouse mammary cancers."	( Targeted cytotoxic luteinizing hormone releasing hormone (LH-RH) anlalogs inhibit growth of estrogen independent MXT mouse mammary cancers in vivo by decreasing cell proliferation and inducing apoptosis. Groot, K; Halmos, G; Nagy, A; Schally, AV; Szepeshazi, K, 1997)	0.49
" Cytotoxic radical AN-201, carrier RC-3094 and their unconjugated mixture administered at the same dosage were ineffective."	( In vivo inhibition of PC-3 human androgen-independent prostate cancer by a targeted cytotoxic bombesin analogue, AN-215. Groot, K; Halmos, G; Nagy, A; Plonowski, A; Schally, AV; Sun, B, 2000)	0.31
" However, moderately elevated doses of the p-DOX equivalent in the conjugate caused toxic effects, making accurate dosage setting essential."	( Polymer conjugates of the highly potent cytostatic drug 2-pyrrolinodoxorubicin. Ibrahimova, M; Rihova, B; Studenovsky, M; Ulbrich, K, 2011)	0.37

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	11 (39.29)	18.2507
2000's	15 (53.57)	29.6817
2010's	2 (7.14)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	2 (7.14%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	26 (92.86%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
bis(4-nitrophenyl)phosphate bis(4-nitrophenyl)phosphate: RN given refers to parent cpd	2	1	aryl phosphate
verapamil Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.. verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.. 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.	2.02	1	aromatic ether; nitrile; polyether; tertiary amino compound
isoflurophate Isoflurophate: A di-isopropyl-fluorophosphate which is an irreversible cholinesterase inhibitor used to investigate the NERVOUS SYSTEM.	2	1	dialkyl phosphate
pyrroles 1H-pyrrole : A tautomer of pyrrole that has the double bonds at positions 2 and 4.. pyrrole : A five-membered monocyclic heteroarene comprising one NH and four CH units which forms the parent compound of the pyrrole group of compounds. Its five-membered ring structure has three tautomers. A 'closed class'.. azole : Any monocyclic heteroarene consisting of a five-membered ring containing nitrogen. Azoles can also contain one or more other non-carbon atoms, such as nitrogen, sulfur or oxygen.	6.29	28	pyrrole; secondary amine
paraoxon [no description available]	2	1	aryl dialkyl phosphate; organophosphate insecticide	EC 3.1.1.7 (acetylcholinesterase) inhibitor; mouse metabolite
n-(2-hydroxypropyl)methacrylamide Duxon: RN given refers to unlabeled cpd	2.06	1
phe-cyclo(cys-tyr-trp-lys-val-cys)thr-nh2 RC 121: RN given refers to (D-Trp)-isomer	2.01	1
lhrh, lys(6)- [no description available]	2	1
daunosamine daunosamine: amino sugar moiety common to adriamycin & daunomycin; RN given refers to (L-lyxo)-isomer; see also ristosamine, (L-ribo)-isomer: 51869-30-8 & acosamine, (L-arabino)-isomer: 41094-24-0; structure	7.06	1
an 207 AN 207: RN given for (2S-cis)-isomer	4.81	10
trelstar Triptorelin Pamoate: A potent synthetic long-acting agonist of GONADOTROPIN-RELEASING HORMONE with D-tryptophan substitution at residue 6.	2.03	1
nitrophenols Nitrophenols: PHENOLS carrying nitro group substituents.	2	1

Condition	Relationship Strength	Studies
Benign Neoplasms [description not available]	2.96	1
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	2.96	1
T-Cell Lymphoma [description not available]	2.06	1
Lymphoma, T-Cell A group of heterogeneous lymphoid tumors representing malignant transformations of T-lymphocytes.	2.06	1
Cancer of Ovary [description not available]	3.34	2
Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.	3.34	2
Carcinoma, Non-Small Cell Lung [description not available]	2.01	1
Cancer of Lung [description not available]	2.01	1
Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.	2.01	1
Lung Neoplasms Tumors or cancer of the LUNG.	2.01	1
Body Weight The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.	2.41	2
Diffuse Mixed Small and Large Cell Lymphoma [description not available]	2.02	1
Experimental Neoplasms [description not available]	2.42	2
Lymphoma, Non-Hodgkin Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.	2.02	1
Breast Cancer [description not available]	3.83	4
Cancer of Prostate [description not available]	4.18	6
Cancer of Endometrium [description not available]	2.94	1
Breast Neoplasms Tumors or cancer of the human BREAST.	3.83	4
Prostatic Neoplasms Tumors or cancer of the PROSTATE.	4.18	6
Endometrial Neoplasms Tumors or cancer of ENDOMETRIUM, the mucous lining of the UTERUS. These neoplasms can be benign or malignant. Their classification and grading are based on the various cell types and the percent of undifferentiated cells.	2.94	1
Adenocarcinoma Of Kidney [description not available]	2.43	2
Cancer of Kidney [description not available]	2.02	1
Carcinoma, Renal Cell A heterogeneous group of sporadic or hereditary carcinoma derived from cells of the KIDNEYS. There are several subtypes including the clear cells, the papillary, the chromophobe, the collecting duct, the spindle cells (sarcomatoid), or mixed cell-type carcinoma.	2.43	2
Kidney Neoplasms Tumors or cancers of the KIDNEY.	2.02	1
Disease Exacerbation [description not available]	2.03	1
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	2.42	2
Colorectal Cancer [description not available]	2.03	1
Colorectal Neoplasms Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.	2.03	1
Hepatocellular Carcinoma [description not available]	2.04	1
Cancer of Liver [description not available]	2.04	1
Carcinoma, Hepatocellular A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.	2.04	1
Liver Neoplasms Tumors or cancer of the LIVER.	2.04	1
Hormone-Dependent Neoplasms [description not available]	2.4	2
Experimental Mammary Neoplasms [description not available]	2.4	2
Adenocarcinoma, Basal Cell [description not available]	2	1
Adenocarcinoma A malignant epithelial tumor with a glandular organization.	2	1
Lymph Node Metastasis [description not available]	2	1
Metastase [description not available]	2	1
Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.	2	1
Weight Reduction [description not available]	2	1
Weight Loss Decrease in existing BODY WEIGHT.	2	1

2-pyrrolino-dox

Description

Cross-References

Synonyms (12)

Research Excerpts

Dosage Studied

Research

Studies (28)

Market Indicators

Research Demand Index: 10.87

Study Types

2-pyrrolino-dox

Description

Cross-References

Synonyms (12)

Research Excerpts

Dosage Studied

Research

Studies (28)

Market Indicators

Research Demand Index: 10.87

Study Types

Related Drugs (12)

Related Conditions (41)